SEN.
`
`COMPANY PROFILE
`
`Page 1 of 18
`
`LUPIN V. SENJU
`' K
`I - I
`‘
`
`Page 1 of 18
`
`SENJU EXHIBIT 2196
`LUPIN v. SENJU
`IPR2015-01097
`
`

`
`President’s Message
`
`The characters that comprise Senju's company name in the Japanese language are “Sen" and “Ju”, which
`
`literally mean “thousand” and “bringing happiness”, respectively. Senju, bringing much (a thousand)
`
`happiness, has an objective to bring a “happiness” to the people associated with us through the
`
`development of original pharmaceutical products for the care of the five senses (eyes, ears, nose, throat
`
`and skin), which ultimately improves the joy of living.
`
`This is our management policy; “Good Company".
`
`We strongly believe that Senju should be a trustworthy and essential company by putting ourselves into the
`
`other person's shoes and acting under the Action Guideline; “If I were you”.
`
`Yukoh Yoshida
`President & CEO
`
`President'sMessage
`
`E
`
`tiDuui1)l7lTKI1l
`
`Page 2 of 18
`
`

`
`
`
`Kagodiuamafieuzyq
`
`Management Policy
`
`Good Company
`
`At Senju Pharmaceutical, our mission is to pursue happiness
`
`for every person associated with the company.
`“Being a good company“ is our management policy.
`As a company that aims to be reliable, necessary, and valuable to society, we are
`committed to pursuing happiness for all people associated with the company, rather than
`simply becoming a “Big Company” that pursues only greater growth and increased sales.
`
`Action Guideline
`
`If I were you
`
`“If I were you”
`Considering others’ viewpoints is the starting point for all of our business activities.
`We should not do to others what we would not like to be done to us.
`
`To treat others in a way that would make us happy if we were treated that way, we
`need to think about and do things from others’ points of view at all times.
`These are the action guidelines that Senju Pharmaceutical employees aim to follow.
`
`5 N
`
`SENSE
`
`SENJU SENSE is a systematic collection of the concepts and values that have
`been carefully handed down over the generations since the founding of our
`company, including our Management Policy “Good Company”. It is a collective
`name for Senju’s values, which are so essential during decision-making and the
`execution of our responsibilities. By ensuring that each and every employee
`shares our SENJU SENSE and works with firm belief in the pursuit of happiness
`for all people associated with the company, we aim to come up with a variety of
`innovative new ideas, thereby ensuring that Senju remains a “Good Company”.
`
`Page 3 of 18
`
`

`
`Ethical Products
`for Medical Professionals
`
`As a manufacturer of ophthalmological drugs, Senju Pharmaceutical
`
`has entered the promising fields on the front lines of medicine.
`
`,.x,\_'k
`
`ll|t\lllknk\lC
`
`
`
`PrescriptionProducts
`
`E
`
`In addition to creating new medicines, particularly
`
`ophthalmic solutions in the field of eye medicine, Senju
`
`Pharmaceutical offers a broad range of generic products
`
`and we steadily implement measures to respond to
`
`changes in the market environment. What's more, we
`also work hard to develop and promote what’s referred to
`
`as “orphan drugs", which treat rare diseases suffered by
`
`extremely small numbers of patients.
`
`Senju Pharmaceutical will take on new challenges every
`
`day with the aim of “maintaining and improving vision” for
`
`as many patients as possible by increasing the added
`
`value of our products by strengthening the information
`
`gathering and communication capabilities we have built
`
`up over many years in the field of ophthalmology and by
`
`accurately identifying treatment needs in the medical
`
`workplace as well as by enhancing our marketing, sales
`
`and logistics functions for promoting activities to
`
`encourage the rapid popularization of our products.
`
`Page 4 of 18
`
`

`
`M M S (Medical Management Supporter)
`
`For Human, for Medical, for Tomorrow.
`
`Senju Pharmaceutical has developed an MMS
`
`(Medial Management Supporter) business to provide
`
`various types of support for the operation of eye
`
`clinics with the aim of contributing to healthcare in
`local communities.
`
`Strong clinic management is essential to providing
`
`high-quality health-care.
`
`Through MMS we provide support to the many
`
`management challenges faced by ophthalmologists,
`including the handling of reforms to various systems,
`
`labor management, the fostering of human resources,
`
`Ma”a9em°"t magazme Medi'Net
`
`‘lividW‘H.mlll’[\
`
`lrailllllxilld
`
`Ll'll_l().‘l«l_\Xlhil\ll[1f1l‘RlLlS
`
`"" I " "
`—
`I
`g I!
`I
`
`I
`
`the handling of tax issues, building partnerships with
`otherfacilities, and improving patient satisfaction.
`What's more, in order to provide ever-changing
`3-
`' I‘
`" I
`‘I a
`healthcare information to ophthalmologists ona
`'
`I
`. uuniuv --I
`timely basis, we provide information via management
`L-
`magazine Medi-Net and ourophthalmologists’ ‘I
`
`management information service website.
`
`Architectural models
`
`I
`
`Page 5 of 18
`
`

`
`Over the Counter (OTC) Products
`
`The Mytear brand was developed from our research into tears.
`
`1‘|t\ll’knk\1t~«.~_\_u
`
`
`
`l~.t~«.t.lpm..llm,.1m.\
`
`U=-Uo..Q4
`GI-‘
`9..
`
`32:=cUca
`
`‘'5s..
`9‘V
`O
`
`Tears are invaluable to our eyes and they have even
`
`is an over-the-counter product containing
`
`been described as “heaven’s eye medicine".
`
`pranoprofen, a nonsteroidal anti-inflammatory drug
`
`Thanks to our ongoing efforts in tear research, in
`
`that has been recognized as an effective and safe
`
`1965 Senju Pharmaceutical launched Japan's first
`
`prescription product.
`
`ever tear-type eye medicine, the artificial tear
`
`Mytear.
`
`Fifteen years later in 1980 we launched Mytear CL
`
`as a contact lens use eye medicine, the first in
`
`Japan that could be applied while still wearing soft
`
`contact lenses. We have continued to develop eye
`
`medicine under the Mytear brand in response to
`
`changing times and changing user needs.
`
`In recent years, we have utilized our product
`
`development capabilities as a manufacturer of
`
`prescription eye medicine and our many years of
`
`marketing experience to launch unique and high
`
`quality products, including Mytear EYETECT, which
`
`Page 6 of 18
`
`

`
`Overseas Activities
`
`When it comes to eye health and the development of
`
`pharmaceutical products, there are no national borders.
`
`all
`
`I. ‘E
`
`ut 1’
`
`Senju Pharmaceutical promotes international
`
`SCIENCE & TECHNOLOGY (BEIJING) CO., LTD.
`
`activities with an eye on the pharmaceutical products
`
`and local manufacturing and sales company SENJU
`
`of tomorrow, beyond the limits of individual countries
`
`WANHE PHARMACEUTICAL (SHENZHEN) CO., LTD.
`
`We are actively seeking to expand the scope of our
`activities and have established local offices in Russia
`
`and Vietnam.
`
`or companies.
`
`As we approach the global age, Senju
`Pharmaceutica|’s overseas activities have become
`
`more diverse than ever. We have promoted the export
`
`of finished products, new product technology and
`
`patent derivations, and we are now active in more
`
`than 50 countries. In order to build partnerships and
`
`introduce the latest technologies and information as
`
`quickly as possible, it is necessary to remain
`
`unconstrained by regional location, industry or scale.
`In the United States, we have established a
`
`subsidiary SENJU USA, INC. with the aim of
`
`promoting research and development in United
`
`States pharmaceutical products. In China, we have
`
`established subsidiary SENJU PHARMACEUTICAL
`
`_<
`
`
`
`sappxpavSEQSIQAO
`
`ll)lt7ll|)lHd
`
`
`
`Ll’ll.l()>l-i.\.\ltdl\()U,1l‘.\l'.lS
`
`Page 7 of 18
`
`

`
`Research and Development
`
`We are using our cutting edge technology and unique research
`
`system to pursue the limitless possibilities of people and science.
`
`“All things in nature have a reason for being.
`
`research into the creation of treatments by using cutting
`
`Today’s common sense is not common sense tomorrow.”
`This is the motto of our researchers.
`
`edge technology to identify the molecules that cause eye
`
`diseases. At our Kobe Creative Center, we promote
`
`Senju Pharmaceutical pursues research and development
`
`research that will lead directly to product development,
`
`through flexible thinking without being constrained by
`
`existing limits or stereotypes through our unique research
`
`including accumulating the data needed for the approval of
`pharmaceutical products. All of our centers work in close
`
`system, which includes international joint research projects
`
`cooperation on this research. Our eyes are fixed firmly on
`
`and collaborative research with industry and academia.
`
`the future. Our goal and aspiration is to develop the
`
`At the Senju Laboratory of Ocular Science and our Oregon
`
`pharmaceutical products that are truly needed by society,
`
`Laboratory in the United States, we carry out basic
`
`safely and as quickly as possible.
`
`I Kobe Creative Center
`
`I Senju Laboratory of Ocular Science
`
`I Oregon Laboratory, United States
`
`
`
`ln_~.«ttlmr.~.\lC~>.LQC
`
`E R
`
`esearchandDevelopment
`
`Page 8 of 18
`
`

`
`Production
`
`Bringing you high quality pharmaceutical products from
`
`factories that meet PIC/S GMP standards
`
`When manufacturing pharmaceutical products, it is
`
`standards at an early stage in anticipation of revisions to
`
`essential to comply with the GMP (Good Manufacturing
`
`GMP standards. Moreover, we have built a system that
`
`Practice) standard for the manufacture of pharmaceutical
`
`allows us to implement ongoing improvements to reduce
`
`products and quasi drugs, from delivery of raw materials
`
`our impact on the environment.
`
`through to shipment of the finished product.
`
`What’s more, because eye medicine is a sterile product,
`
`We will continue to deliver a steady supply of high quality
`pharmaceutical products to Japan and the world from
`
`there is a need for sterile manufacturing facilities that
`
`factories that combine state-of-the-art manufacturing
`
`guarantee a high level of sterility, and a need for the
`
`facilities with a state-of-the-art manufacturing environment.
`
`installation of testing equipment and quality control.
`
`Senju Pharmaceutical works to comply with PIC/S-GMP
`
`PIC/S: The Pharmaceutical Inspection Convention and
`Pharmaceutical Inspection Co-operation Scheme
`
`I Manufacturing Plant Karatsu
`
`I Manufacturing Plant Fukusaki
`
`Status of |SO14001 Certification Acquisition : Plant Fukusaki in December 2007/ Plant Karatsu in December 2014
`
`
`
`<1‘u\u>\\‘I41\‘:J\()
`
`uopanpold
`
`
`
`
`
`&l'll:l0?idA.\ttdl\lOD.'1fI\2lS
`
`Page 9 of 18
`
`

`
`Animal Health
`
`Using the pharmaceutical technologies developed for
`
`humans to develop health products for companion animals
`
`People are not the only living things to use sense
`
`organs such as the eyes and ears to collect
`
`abundant information for use in their everyday lives.
`
`Sense organs are also an essential part of the daily
`
`lives of the pets who live side by side with humans.
`
`In recent years, improved living standards and
`
`medical advances have increased the length of time
`
`that pets and humans can live side by side, leading
`
`to increased risk from ageing associated lifestyle
`
`diseases and increased importance of the sense
`
`organs in pets’ daily lives. Senju Pharmaceutical has
`
`continued to utilize the pharmaceutical development
`
`technologies we have accumulated over many years
`
`of developing human sensory organ pharmaceutical
`
`products in the development and promotion of animal
`
`pharmaceutical products and other animal products,
`
`helping our pets to live long and happy lives.
`
`.-.rg_c
`
`
`
`lhcsiclt-:1:’<.\lu
`
`
`
`lhcscilptlmnl’10Lluct.~
`
`E3
`
`
`
`AnimalHealth
`
`Page 10 of 18
`
`

`
`Alleviation ar the Five Senses I
`
`Page 11 of 18
`
`

`
`Alleviation for the Five Senses I
`
`SEN
`
`Senju Pharmaceutical Co., Ltd.
`
`2-5-8, Hirano-machi, Chuo-ku, Osaka
`
`TEL : O6-6201-2512 (main switchboard)
`FAX :06-6226-0406
`
`URL : http://www.senju.co.jp
`
`e 12 of 18
`
`Page 12 of 18
`
`

`
`Milestones in Our History
`
`Capital increased to 1,415,500,000 yen.
`NSAID Ophthalmic Solution, "NIFLAN", launched.
`Los Angeles Office opened in USA.
`Kobe Creative Center completed.
`Yokohama Branch opened.
`Kobe Branch opened.
`Chiba Branch and Saitama Branch opened.
`NSAID Ophthalmic Solution, "BRONUCK", launched.
`A laboratory completed in Oregon, USA.
`The European Office opened.
`Beijing Office opened in China.
`Senju USA, Inc. established.
`Senju Laboratory of Ocular Science, Kobe Laboratory
`completed.
`Yukoh Yoshida becomes the President of the Company.
`Senju Medical Consulting (Shanghai) Co., Ltd. established in
`Shanghai, China.
`Osaka Logistical Warehouse opened.
`Manufacturing Plant Karatsu built at 4228-1 Ishishi,
`Karatsu-shi, Saga.
`Ophthalmic Solution for Glaucoma Ocular Hypertension,
`“LUMlGAN", launched.
`Senju Pharmaceutical Science & Technology (Beijing) Co.,
`Ltd. established.
`Hanoi Office opened in Hanoi, Vietnam.
`Ophthalmic Solution for Glaucoma Ocular Hypertension,
`“A|PHAGAN", launched.
`Moscow Office opened in Moscow, Russia.
`Saitama Office opened.
`Chiba Office opened.
`Shizuoka Satellite Office opened.
`Senju Wanhe Pharmaceutical Shenzhen Corp. established in
`Shenzhen, China as a joint company.
`
`The Company founded at 12-Ishigatsuji-cho, Tennoji-ku,
`Osaka. Start-up capital of 195,000 yen. President, Hiroshi
`Tsuzuki.
`Injection Product for Neutropenia, "PANILTIN", launched.
`Reishin Tanimura becomes the President of the Company.
`Company head office relocated to 2-42 Hirano-machi,
`Higashi-ku, Osaka.
`Manufacturing plant relocated to 482 lwazono-cho, Ashiya City.
`Agreement concluded with Takeda Pharmaceutical Company
`Limited for the sole distribution of Senju Products.
`Capita increased to 780,000 yen.
`Masao Yoshida becomes the President of the Company.
`Capita increased to 3,000,000 yen.
`Tokyo Branch opened.
`Ophthalmic Solution for Cataracts, "CATALIN", launched.
`Capita increased to 6,000,000 yen.
`Implementation of the City Planning Act meant the company
`reloca ed the Ashiya Plant to a newly-built plant at 416
`lwazono-cho.
`Fukuoka Branch opened.
`Capita increased to 9,000,000 yen.
`Capita increased to 13,500,000 yen.
`Itami Plant newly built for the manufacture of ingredients at 1-1
`Oshika-Sakuragaoka, Itami City.
`Capita increased to 18,000,000 yen.
`Laboratory and attached facilities newly built at the Ashiya
`Plant.
`Capita increased to 30,000,000 yen.
`Artificial Tear Ophthalmic Solutions, “MYTEAR", launched.
`Company head office relocated to 1-83 Doshin-cho, Kita-ku,
`Osaka.
`Nagoya Branch opened.
`Capital increased to 75,000,000 yen.
`Sendai Branch opened.
`Sapporo Branch opened.
`Laboratory completed in the Itami Plant.
`Company head office and Osaka Branch relocated to 3-28
`Hirano-machi, Higashi-ku, Osaka (Amakasu Building).
`Hiroshima Branch opened.
`Capital increased to 150,000,000 yen.
`Manufacturing Plant Fukusaki built at 767-7 Kazukanonishi,
`Saiji, Fukusaki-cho, Kanzaki-gun, Hyogo.
`Capital increased to 225,000,000 yen.
`Shoji Yoshida becomes the President of the Company.
`Company head office relocated to 3-6-1 Hirano-machi,
`Higashi-ku, Osaka (7'“ Floor of Hirano-machi Century Building).
`Ophthalmic Solution for use on contact lens, "MYTEAR CL",
`launched.
`Capital increased to 450,000,000 yen.
`A biological laboratory completed in the Itami Research
`Laboratory.
`Capital increased to 1,050,000,000 yen.
`Utsunomiya Branch, Matsumoto Branch, and Takamatsu
`Branch opened.
`Kyoto Branch opened.
`lntraocular irrigating Solution, "OPEGUARD MA", launched.
`
`September
`November
`April
`July
`
`Page 13 of 18
`
`

`
`
`
`31gciIdrueauiog
`
`
`
`C-I'll.-l().‘l<l\V\'<ll\lOL)'ll'l\l.'-IS
`
`Company Profile
`
`Trade Name
`Principal Office
`
`Senju Pharmaceutical Co., Ltd.
`2-5-8, Hirano-machi, Chuo-ku, Osaka, 541-0046, Japan
`TEL: +81-6-6201-2512
`FAX: +81 -6-6226-0406
`
`Date of Incorporation April, 1947
`Representative
`Yukoh Yoshida
`Capital
`1.4 billion yen
`Employees
`861 (as of March 2015)
`Sales
`35 billion yen (as of March 2015)
`Accounting Period
`March
`Business Content
`(1) Pharmaceutical business: manufacture and sale of prescription eye, ear,
`nose and throat medicines, contact lens solutions and animal medicines
`(2) Other business: manufacture and sale of raw materials for cosmetics
`
`I Matters related to officers
`
`Member of the Board of Directors
`
`Executive Officer
`
`Shoji Yoshida
`Yukoh Yoshida
`Shuhei Yoshida
`
`Chairman of the Board
`President & CEO
`Executive Vice President & COO
`Head of Corporate Management Division and Business Strategy Division
`
`Takeshi Sugisawa Head of Business Development Division
`Hidemi Shimoji
`Head of Research and Development Division
`Mikio Ogawa
`Head of Overseas Business Division
`Tomio Maenaka
`Head of Production Division
`
`M“S“Y°Sl“ Azuma
`
`Takashi Masuda
`
`Akemi Yamasaki
`
`Ma"39‘“9 EX°““Ve °"i°°'
`Head of Laboratory, Senju Laboratory of Ocular Science
`Managing Excutive Officer
`Head of Pharmaceutical Marketing Division
`Corporate Auditor
`
`Michinari Wada
`Takahiro Ogawa
`
`Head of Reliability Assurance Division
`President of SENJU USA (secondment)
`
`I Trends in Sales and Current Profits
`
`Sales (unit: ¥ billion)
`35.0
`
`30.0
`
`25.0
`
`Current Profits (unit: ¥ billion)
`9_o
`8.0
`7.0
`6.0
`5.0
`4.0
`3.0
`2.0
`1.0
`0
`
`2011
`
`2012
`
`2013
`
`2014
`
`Sales(unit: ¥ billion) :0: Current Profits (unit: ¥ billion)
`
`Sales
`
`Current profits
`
`.
`
`2011
`25.1
`
`4.4
`
`2012
`28.6
`
`2.6
`
`2013
`33.0
`
`5.1
`
`Unit: Billion yen
`
`Page 14 of 18
`
`

`
`iCCS (Overseas)
`
`I Laboratories and Offices
`
`OSENJU LABORATORY OF OCULAR SCIENCES (SLOS)
`OTRADI Bioscience Incubator, 4640 SW Macadam Ave., Suite 2000, Portland, OR 97239, U.S.A.
`Te I: +1-503-748-5202
`Fax: +1-503-748-5204
`.$ENJU PHARMACEUTICAL 00., LTD. BEIJING OFFICE
`Unit 3602, Fortune Plaza Office Tower A, No.7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C
`Tel: +86-10-6533-0200
`Fax: +86-10-6536-1329
`
`OSENJU PHARMACEUTICAL co., LTD. Hanoi Representative Office
`Room 1314, Level 13, Ha Noi Towers, 49 Hai Ba Trung, Hoan Kiem District, Ha Noi, Vietnam
`Tel: +84-4-3934-3890
`Fax: +84-4-3934-3966
`OMoscow Representative Office of Senju Pharmaceutical Co., Ltd.
`Office No.105, 1st floor, str. 6, dom 1A, Tretiy Nizhnelikhoborskiy proyezd, Moscow 125371, Russian Federation
`
`Isubsidiaries
`
`OSENJU USA, INC.
`21700 Oxnard Street, Suite 1070 Woodland Hills, CA 91367, U.S.A.
`Tel: +1-818-719-7190
`Fax: +1-818-719-7195
`
`OSENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) co., LTD.
`Unit 3602, Fortune Plaza Office Tower A, No.7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C
`T e I: +86-10—6533—020O
`Fax: +86—10-8536-1329
`
`OSENJU WANHE PHARMACEUTICAL (SHENZHEN) co., LTD.
`Block B, Wanhe Technology Complex, Hi-tech Park, Guangming District, Shenzhen, Guangdong Province, China
`
`
`
`
`
`C-l’lH().‘ItI\\'\'(ll\l(_)_)ll'l\lf-IS
`
`Page 15 of 18
`
`

`
`Offices (Japan)
`
`I Head Office
`
`Hirano-machi Century Building
`2-5-8, Hirano-machi, Chuo-ku, Osaka, 541-0046
`TEL: +81-6-6201-2512 (main switchboard) FAX: +81-6-6226-0406
`
`I Branches and Groups
`
`x”
`
`(Wdvf)mmo
`
`[Northern Japan Branch]
`.5app°"° omcel 5app°"° G"°“p
`Takeda 3aPP°r° BU“di“9»
`13-4, Kitaichijonishi, Chuo-ku, Sapporo-shi, Hokkaido, 060-0001
`TE‘-I +81-11-221-2743
`'5°"°a‘ °"‘°°v T°"°k" ""5" G'°“Pv T°“°"“ 5°°°"“ °'°“P
`Takeda Sendai B'~‘"di"9
`2-13-21, H°"°h°i A°b3'kU» 3e"dai'Shi» 'V“Ya9i- 930-0014
`TEL: +31-22454-2233
`
`[Saitama Kitakanto Shinetsu Branch]
`Outsunomiya Office, Kita—Kanto Group
`Ch”° Ut5“”°miYa B“”di”9
`3-1-1 Hi9aShiShUk“9°- UiSU"°miYa-Shh T°°hi9ii 321-0953
`TEL1*31-23-533-525°
`Osaitama Office, Saitama Group, Shinetsu Group
`82 Om“/3 B““di”9
`1-11-3, Sakuragicho, Omiya-ku, Saitama-shi, Saitama, 330-0854
`TE'-5 +81-43-558-234°
`[Karma Branch]
`Qchiba Office, Chiba Group
`Lalaport Mitsui Building
`2-1-1, Hamacho, Funabashi-shi, Chiba, 273-0012
`
`[Tokai Branch]
`.Nagoya Office, Tokai First Group, Tokai Second Group
`Nishiki Park Building
`2_4_3! Nishiki’ Naka_ku’ Nagoya_shi’ Aichii 45o_0003
`TEL: +81-52-211-2560
`Oshizuoka Satellite Office, Tokai First Group (Shizuoka base)
`Mitsui Seimei Shizuoka—ekimae Building
`11-7, Kuroganecho, Aoi—ku, Shizuoka—shi, Shizuoka, 420-0851
`TEL: +81—52—211—2560 (Nagoya Office)
`
`maiisai Shikoku Biaiichi
`.Ky°i° office’ Kyoto Group
`Sumitomo Seimei Kyoto Building
`62, Tsukihokocho, Shinmachihigashiiru, Shijodori,
`Shimogyo—ku, Kyoto—shi, Kyoto, 600-8492
`TEL: +81—75—229—6549
`Oosaka Office, Osaka First Group, Osaka Second Group
`Takeda i.iii.ano_machi Buiiding
`2-4-9, Hirano—machi, Chuo-ku, Osaka, 541-0046
`TEL: +81-6-6226-0403
`.“°be °"‘°ev “°b° G'°"P
`K°be Homachi B”"di”9
`121» "°'“a°h'» Ch“°"<“v K°be'5“'» "'V°9°» 65043032
`
`OTokyo Office, Tokyo First Group, Tokyo Second Group, Tokyo Third Group
`MFPR Nihonbashihonciio Buiiding
`3_7_2! Nihonbashihoncim Chuo_ku_ -i—°ky0_ 103_0023
`TEL: +81-3-5643-1950
`.Yokohama Office, Yokohama Group
`Hi9a5h“°t5'-‘K3 West B””di”9
`90-6, Kawakamicho, Totsuka-ku, Yokohama-shi, Kanagawa, 244-0805
`TEL? +81'45'828'1381
`
`.Takama‘5" °ffi°°l 5hik°k" emu”
`Takamatsu Daiichi Seimei Building
`1-3-2, Kotobukicho, Takamatsu-shi, Kagawa, 760-0023
`TEL3 +31'87'822'9492
`[Kyushu Chugoku Branch]
`.Hiroshima Office, Chugoku Group
`Takeda Hiroshima Buiiding
`1-25, Komachi, Naka-ku, Hiroshima-shi, Hiroshima, 730-0041
`TEL: +81-82-248-2023
`
`OFukuoka Office, Kyushu First Group, Kyushu Second Group
`Fukuoka Takeda Building
`9-12, Shimokawabatamachi, Hakata-ku, Fukuoka-shi, Fukuoka, 812-0027
`TEL: +81-92-271-2390
`
`I Manufacturing Plants and Research Laboratories
`
`.Manufacturing Plant Karatsu
`4228-1, lshishi, Karatsu-shi, Saga, 847-0832
`TEL: +81-955-78-1050
`
`QManufacturing Plant Fukusaki
`767-7, Saiji, Fukusakicho, Kanzaki-gun, Hyogo, 679-2285
`TEL: +81-790-22-2671
`
`.Kobe Creative Center
`1-5-4, Murotani, Nishi-ku, Kobe-shi, Hyogo, 651-2241
`TEL: +81-78-997-1010
`
`Osenju Laboratory of Ocular Science
`BMA
`1-5-5, Minatojimaminamimachi, Chuo-ku, Kobe-shi, Hyogo, 650-0047
`TEL: +81-78-303-4031
`
`Page 16 of 18
`
`

`
`P1'O d1lCtS (Overseas)
`
`I Asia
`
`China
`
`<>Pranopu|in (Senju)
`CCata|in (Senju)
`Bronuck (Senju)
`©Sodium Hyaluronate (Senju)
`*Talymus (Senju)
`
`South Korea
`
`<>Pranopu|in (JW Shinyak)
`i‘:Lomef|on (JW Shinyak)
`OTimobetalol-LA (Taejoon)
`Bronuck (Taejoon)
`ISenju CL (JW Pharma)
`IFrenz Eye Drops (JW Pharma)
`
`Hong Kong
`Ocatalin (Takeda Hong Kong)
`
`Taiwan
`
`Ocataiin K (Takeda Taiwan)
`
`Philippines
`Ocataiin (Takeda Philippines)
`
`Indonesia
`CCatalin (P.T. Takeda Indonesia)
`
`Thailand
`
`Pakistan
`
`Ocatalin (Takeda Thailand)
`
`CCatalin (Helix)
`
`Vietnam
`
`Bronuck (Senju)
`©Tearba|ance (Senju)
`
`India
`
`OG|ucotimLA (Centaur)
`Ocubro (Centaur)
`
`
`
`(szosxazxo)Slzmpoild
`
`I Americas
`
`United States
`
`Olstalol (B+L)
`Prolensa (B+L)
`Bromday (B+L)
`OBepreve (B+L)
`ODurezo| (Alcon)
`
`Mexico
`
`<>Nif|an (SIFI)
`
`Brazil
`
`Puerto Rico
`
`Oclarvisol (Allergan)
`
`ODurezo| (Alcon)
`
`Canada
`
`ODurezo| (Alcon)
`
`Bulgaria
`Yellox (Valeant)
`
`Hungary
`Yellox (Va|eant)
`
`Switzerland
`
`Yellox (valeant)
`
`Saudi Arabia
`
`CCata|in (Saudi Arabian Drug Store)
`
`I Europe and the Middle East
`
`Poland
`
`Ocatalin (Pharmaheads)
`Yellox (valeant)
`
`Russia
`
`CCata|in (Senju)
`
`Romania
`
`<>Pranoflog (SIFI)
`
`Belgium
`<>Pranox (MEDA)
`
`Portugal
`.C|arvisan (LUSO)
`Yellox (Va|eant)
`
`Italy
`OC|arvisan (Allergan)
`<>Pranoflog (SIFI)
`Yellox (valeant)
`
`Germany
`Yellox (Va|eant)
`
`United Kingdom
`Yellox (Va|eant)
`
`Austria
`
`Yellox (valeant)
`
`France
`
`Yellox (Va|eant)
`
`Netherlands
`
`Yellox (valeant)
`
`Republic of Ireland
`Yel ox (valeant)
`
`Sweden
`
`Yel ox (Valeant)
`
`Norway
`Yel ox (valeant)
`
`Denmark
`
`Yel ox (Va|ea nt)
`
`Finland
`
`Yel ox (valeant)
`
`Spain
`Yel ox (valeant)
`
`Product names in Japan: O CATALIN Ni‘: LOMEFLON <> NIFLAN Kl BRONUCK © TEARBALANCE * TALYMUS I Generic medicine 0 Not sold in Japan
`>l<()=Marketlng Authorization Holder
`
`As of July 2015
`
`Page 17 of 18
`
`

`
`Products (Japan)
`
`Prescription Products
`
`[Eye products]
`Inflammation and allergy
`ELICS OPHTHALMIC SOLUTION 0.25%
`ODOMEL OPHTHALMIC SOLUTION 0.02%
`ODOMEL OPHTHALMIC SOLUTION 0.05%
`ODOMEL OPHTHALMIC SOLUTION 0.1%
`CROMOFERON OPHTHALMIC SOLUTION 2%
`KETAS OPHTHALMIC SOLUTION 0.01%
`NIFLAN OPHTHALMIC SOLUTION 0.1%
`VISUALIN OPHTHALMIC SOLUTION 0.02%
`VISUALIN OPHTHALMIC SOLUTION 0.05%
`VISUALIN SOLUTION FOR EYE EAR AND NOSE 0.1%
`BRONUCK OPHTHALMIC SOLUTION 0.1%
`LYSOTEAR OPHTHALMIC SOLUTION 0.5%
`LEVOCABASTINE 0.025% OPHTHALMIC SOLUTION [TS]
`
`Antibacterial and antifungal agents
`GATIFLO OPHTHALMIC SOLUTION 0.3%
`BACCIDAL OPHTHALMIC SOLUTION 0.3%
`PIMARICIN 1% Ointment [SENJU]
`PIMARICIN OPHTHALMIC SOLUTION 5% [SENJU]
`BESTRON OPHTHALMIC SOLUTION 0.5%
`LOMEFLON OPHTHALMIC SOLUTION 0.3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`Over the Counter (OTC) Products
`
`Eye medicine
`Mytear EYETECT
`Mytear EYETECT ALPITATTO
`Mytear EYETECT ALPITATTO-N
`Mytear ALPITATTO EXot
`Mytear ALPITATTO N EXa
`NewMytear A
`Mytearclean Cool
`Mytear Vitamin B2BsE
`Mytear Vido
`Mytear Fresh40
`
`Animal Medicines
`
`STEROP
`TEAROSE
`PAPITEIN
`MIMIENA
`LIGHT CLEAN
`LOMEWON
`ONE CLEAN
`
`
`
`(uzdzf)Slonpoxd
`
`Other
`ARTIFICIAL TEAR MYTEAR OPHTHALMIC SOLUTION
`SCOPISOL SOLUTION FOR EYE
`SOFTEAR OPHTHALMIC SOLUTION 0.02%
`TAZIN TABLETS 30
`TALYMUS OPHTHALMIC SUSPENSION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.3%
`TEARBALANCE MINIMS OPHTHALMIC SOLUTION 0.3%
`
`[Ear, nose and throat products]
`VISUALIN SOLUTION FOR EYE EAR AND NOZE 0.1%
`BESTRON FOR EAR AND NOSE 1%
`LOMEFLON SOLUTION FOR EAR 0.3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`Contact Lens Products
`
`03/hard use
`Mytear Hard Lens Wearing Solution (designated quasi-drug)
`NewMytear Easy S
`NewMytear CL 0; Lens Care
`
`Cataracts
`CATALIN FOR OPHTHALMIC 0.005%
`CATALIN-K FOR OPHTHALMIC 0.005%
`
`Glaucoma
`AIPHAGAN OPHTHALMIC SOLUTION 0.1%
`MIKELAN OPHTHALMIC SOLUTION 1%
`MIKELAN OPHTHALMIC SOLUTION 2%
`MIKELAN LA OPHTHALMIC SOLUTION 1%
`MIKELAN LA OPHTHALMIC SOLUTION 2%
`LATANOPROST OPHTHALMIC SOLUTION 0.005% SENJU
`LUMIGAN OPHTHALMIC SOLUTION 0.03%
`
`Surgical aids
`INDOMELOL OPHTHALMIC SOLUTION 0.5%
`OXYBUPROCAINE HYDROCHLORIDE MINIMS OPHTHALMIC SOLUTION 0.4“/I [SENJU]
`OPEGUARD-MA INTRAOCULAR IRRIGATING SOLUTION
`OPEGUARD Neo Kit INTRAOCULAR IRRIGATING SOLUTION 0.0184‘/o
`OPELEAD 0.5 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD 0.6 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`0PELEAD1.1 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD HVO.4 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD HVO,6 OPHTHALMIC VISCOELASTIC PREPARATION 1"/n
`OPELEAD HVO.85 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`
`Eye medicine for use with contact lens
`NewMytear CL a
`NewMytear CL Cool a
`NewMytear CL Cool Hi a
`NewMytear CL Ice Crush
`FirstMytear CL-P
`FirstMytear CL-G
`FirstMytear CL-B
`
`Animal Quasi-Drugs
`
`BEST FRIENDS EAR CLEANER A
`BEST FRIENDS EAR CLEANER G
`
`Animal Health Products
`
`BEST FRIENDS RINSE IN SHAMPOO
`BEST FRIENDS TREATMENT MIST TYPE
`
`As of July 2015
`
`Page 18 of 18